Remove 2019 Remove Communication Remove Documentation
article thumbnail

Navigating the regulatory challenge of PFAS for pharmaceutical manufacturers

European Pharmaceutical Review

billion Global concerns surrounding PFAS, or per- and polyfluoroalkyl substances, are due to their well-documented effects on human health and the environment. This may cover anything from waste management, decontamination and health and safety issues to project controls including scheduling, resource tracking and communications.

article thumbnail

Pharmacist to Clinical Strategy Leader: Brendan Doran on Building a Career in Biotech

The Nontraditional Pharmacist

So, we would have spoken in 2019. And then how do you develop documents to basically get approval from the FDA to study your drug in humans? The last time we spoke, biosimilars were this new thing and everyone was trying to figure out what was going to happen regulatory-wise and a lot of other changes since then. It’s 2025.

FDA
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How ICH E6 (R3) is changing clinical trials

Pharmaceutical Technology

According to ACRO’s 2025 RBQM survey, 96% of trials now include at least one RBQM component (vs just 53% in 2019), with centralized monitoring and remote oversight becoming standard practice 1. To explore how Zelta can support your organization’s clinical data management needs, download the document below.

article thumbnail

From data to impact: How real-world evidence will transform healthcare

pharmaphorum

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

article thumbnail

White paper reveals pathway for digital therapeutics use in Italy

pharmaphorum

The experts were also involved in the “Digital Therapeutics for Italy – #DTxITA”, established in 2019 to encourage the implementation of DTx in Italian institutions and healthcare systems. Healthware Group, an international integrated consulting group also based in Italy, contributed to the white paper.

article thumbnail

Teva faces EU antitrust probe over MS drug Copaxone

pharmaphorum

The Commission will also examine whether Teva may have launched a communication campaign to create a “false perception” about the health risks of prescribing generic competitors, aimed at healthcare professionals and hospitals.

article thumbnail

New regulatory relief to benefit Europe’s pharma SMEs

European Pharmaceutical Review

As small and medium-sized enterprises (SMEs) often face unfair competition when doing business in Europe, through the (SME) Relief Communication, the European Commission (EC) has proposed new measures to provide short-term relief, boost long-term competitiveness, and improve equality in the business environment across the Single Market in Europe.